Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CASR | P41180 | 6/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077923 | 0.88 | CASR (0.42) | SLC6A4EPHX2CASR | |
| SCHEMBL13077926 | 0.87 | EPHX2 (0.52) | SLC6A4EPHX2CASRMETAP2METAP1 | |
| SCHEMBL13077637 | 0.86 | EPHX2 (0.42) | EPHX2CASRMETAP2METAP1KMT2A | |
| SCHEMBL13078026 | 0.86 | EPHX2 (0.47) | SLC6A4EPHX2CASRMETAP2METAP1 | |
| SCHEMBL13077608 | 0.85 | ALDH1A1 (0.46) | EPHX2CASRMETAP2METAP1KMT2A | |
| SCHEMBL13040883 | 0.84 | CNR1 (0.42) | CNR1CNR2SLC6A4EPHX2CASR | |
| SCHEMBL13077971 | 0.83 | EPHX2 (0.39) | SLC6A4EPHX2CASR | |
| SCHEMBL13077610 | 0.83 | CASR (0.45) | EPHX2CASRMETAP2METAP1 | |
| SCHEMBL13077638 | 0.83 | CASR (0.45) | EPHX2CASRMETAP2METAP1 | |
| SCHEMBL13077968 | 0.83 | CASR (0.40) | EPHX2CASRMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | C1R, C3AR1, PTH1R | CNR1 49/4885CNR2 175/4885SLC6A4 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.